B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

GBA1

MOLECULAR TARGET

glucosylceramidase beta 1

UniProt: P04062NCBI Gene: 262918 compounds

GBA1 (glucosylceramidase beta 1) is targeted by 18 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting GBA1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1tamoxifen5.88358
2duvoglustat4.3476
3mexiletine3.9953
4miglitol3.6136
5afegostat3.0420
6ambroxol2.4811
7dideoxyiminoxylitol1.956
8Chlorhexidine1.102
9Genistein0.691
101-Deoxynojirimycin0.691
11trichostatic acid [Supplementary Concept] related to trichostatin0.691
12bdb chembl21701990.691
13bdb chembl33540160.691
14bdb chembl33540190.691
15bdb chembl33540290.691
16bdb chembl33540320.691
17bdb chembl33540150.691
18bdb chembl33540170.691

About GBA1 as a Drug Target

GBA1 (glucosylceramidase beta 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 18 compounds with documented GBA1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

GBA1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.